Conclusion: This study shown that the burden of disease in axial PsA has a significantly different between genders. Female patients with PsA who have axial involvement have higher disease activity, physical disability, functional limitation and higher depression and anxiety risk than male patients. Therefore, we suggest that new strategies should be developed for more effective treatment of axial PsA in female patients.

Disclosure of Interests: Kemal Nas: None declared, Erkan Kilic: None declared, Ibrahim tekeoglu: None declared, Remzi Cevik: None declared, Berat Cem: None declared, Nevzat Keskin: None declared, Sevapt Aker Kasman: None declared, Hakan Akkan: None declared, Nilay Sahin: None declared, Gizem Cengiz: None declared, Nihan Cuzdan: None declared, Ilknur Albayrak Gezer: None declared, Dilek Keskin: None declared, Ceviri Müköglu: None declared, HaticeBorder: None declared, Şebnem Atanem: None declared, Aşa Bal: None declared, Mehmet Tuncay Duruduz Girit: no financial support from: Abive, Speakers bureau: Novartis, AMGEN, Abdullah, Ilio, Okan Kucukakkas: None declared, Ozan Volkan Yurdakul: None declared, Meltem Almekilioglu: None declared, Yildiray Aydin: None declared, Gul Devrimsel: None declared, Kevser Gok: None declared, SAMI HİZMETLI: None declared, Ayhan Kamant: None declared, Yasar Keskin: None declared, Halil Kocabas: None declared, Ozrun Kutluk: None declared, Nesrin Şen: None declared, Omer Faruk Sendur: None declared, Murat Toprak: None declared, Sena Tolu: None declared, Tiraje Tuncer: None declared


FR10457

SECUKINUMAB PROVIDES SIGNIFICANT AND SUSTAINED IMPROVEMENT IN NAIL PSORIASIS AND SIGNS AND SYMPTOMS OF PsORIASTIC ARTHRITIS IN PATIENTS WITH NAIL PHENOTYPE: 52-WEEK RESULTS FROM THE PHASE III FUTURE 5 STUDY

Peter Nash1, Philip J. Mease2, Bruce Kirkham2, Alejandra Balsa3, Asil Singha4, Emard Quebe-Fehling5, Luminita Pricop7, Corine Gaillez6.

1University of Queensland, Brisbane, Australia; 2Swedish Medical Center and University of Washington, Seattle, United States of America; 3Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 4Hospital La Paz – IASP, Madrid, Spain; 5Southwest Rheumatology, Dallas, United States of America; 6Novartis Pharma AG, Basel, Switzerland; 7Novartis Pharmaceuticals Corporation, East Hanover, United States of America

Background: Nail psoriasis (PsO) is present in up to 80% in psoriatic arthritis (PsA) patients (pts) and associated with significant pain, psychosocial disability, decreased physical function and quality of life (QoL).1 Nail PsO is considered as one of the six core PsA domains by GRAPP2 and is a predictor of severe disease with joint involvement and structural damage. Secukinumab (SEC) has demonstrated efficacy for pts with nail PsO in the TRANSFIGURE study3 and significant improvement in signs and symptoms of PsA in the FUTURE 5 study4 Objectives: To evaluate the efficacy of SEC on nail PsO and other facets of disease in the nail subset from the FUTURE 5 study through 52 weeks (wks).

Methods: Pts (N=996) with active PsO were randomised to subcutaneous SEC 300 mg loading dosage (LD; 300 mg), 150 mg LD (150 mg), 150 mg no LD or placebo (PBO). All groups received SEC or PBO at baseline (BL), Wks 1, 2, 3, and 4, and then every 4 wks. Efficacy assessments through Wk 52 included mNAPSI, ACR, PASI, HAQ-DI, SF-36 PCS, PsAQoL and resolution of dactylitis and enthesitis. Analyses through Wk 52 included mNAPSI, ACR, PASI, HAQ-DI, SF-36 PCS, PsAQoL and resolution of dactylitis and enthesitis. Analyses through Wk 52 included mNAPSI, ACR, PASI, HAQ-DI, SF-36 PCS, PsAQoL and resolution of dactylitis and enthesitis.

Conclusion: Secukinumab provided sustained improvements in nail disease, signs and symptoms of PsO, physical function and QoL through 52 wks in pts with PsA and moderate to severe nail PsO.

REFERENCES:

Table: Summary of results

<table>
<thead>
<tr>
<th>Variable</th>
<th>Wk 300 mg LD</th>
<th>150 mg LD</th>
<th>150 mg no LD</th>
<th>PBO N=231</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR201</td>
<td>16</td>
<td>66.7*</td>
<td>60.0*</td>
<td>61.4*</td>
</tr>
<tr>
<td>52</td>
<td>81.2 (133)</td>
<td>73.7 (118)</td>
<td>77.8 (136)</td>
<td>-</td>
</tr>
<tr>
<td>ACR501</td>
<td>16</td>
<td>43.1*</td>
<td>40.7*</td>
<td>32.0*</td>
</tr>
<tr>
<td>52</td>
<td>54.1 (133)</td>
<td>45.8 (118)</td>
<td>50.7 (136)</td>
<td>-</td>
</tr>
<tr>
<td>PASI 902</td>
<td>16</td>
<td>52.0*</td>
<td>36.8*</td>
<td>31.0*</td>
</tr>
<tr>
<td>52</td>
<td>62.3 (69)</td>
<td>50.7 (75)</td>
<td>49.3 (75)</td>
<td>-</td>
</tr>
<tr>
<td>HAQ-DI3</td>
<td>16</td>
<td>-0.6*</td>
<td>-0.5*</td>
<td>-0.5*</td>
</tr>
<tr>
<td>52</td>
<td>-0.6 (132)</td>
<td>-0.6 (117)</td>
<td>-0.6 (137)</td>
<td>-</td>
</tr>
<tr>
<td>SF-36 PCS3</td>
<td>16</td>
<td>6.0*</td>
<td>6.9*</td>
<td>6.0*</td>
</tr>
<tr>
<td>52</td>
<td>8.0 (134)</td>
<td>6.71 (123)</td>
<td>7.63 (137)</td>
<td>-</td>
</tr>
<tr>
<td>PsAQoL4</td>
<td>16</td>
<td>-3.6*</td>
<td>-3.6*</td>
<td>-3.0*</td>
</tr>
<tr>
<td>52</td>
<td>-3.9 (134)</td>
<td>-4.2 (122)</td>
<td>-3.8 (137)</td>
<td>-</td>
</tr>
<tr>
<td>Resolution of enthesitis, %4</td>
<td>16</td>
<td>58.2*</td>
<td>56.8*</td>
<td>47.2*</td>
</tr>
<tr>
<td>52</td>
<td>81.5 (92)</td>
<td>68.7 (80)</td>
<td>70.7 (82)</td>
<td>-</td>
</tr>
<tr>
<td>Resolution of dactylitis, %4</td>
<td>16</td>
<td>63.8*21</td>
<td>52.6*21</td>
<td>59.2*21</td>
</tr>
<tr>
<td>52</td>
<td>78.6 (52)</td>
<td>76.6 (49)</td>
<td>80.3 (66)</td>
<td>-</td>
</tr>
</tbody>
</table>

1P<0.001; 2P<0.01; 3P<0.05 vs. PBO. NRI data for binary and MMRM data for continuous variables presented at Wk 16. Observed data presented at Wk 52. % responders (n). Data from pts with PsA (3% BSA: N=75 [300 mg]; 87 [150 mg]; 64 [150 mg no LD] and 118 [PBO]). Mean change from baseline (n). Data from pts with enthesitis/dactylitis at BL: N=98 [300 mg]; 89/7 [150 mg no LD] and 140/102 [PBO]. N, number of pts with nail PsO in each group; n, number of evaluable pts at Wk 52.

Disclosure of Interests: Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB.
Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB, Bruce Kirkham Grant/research support from: Abbvie, Janssen, Lilly, Novartis, Roche, UCB, Consultant for: Abbvie, Janssen, Lilly, Novartis, Roche, UCB, Speakers bureau: Abbvie, Janssen, Lilly, Novartis, Roche, UCB, Alejandro Balsa Grant/research support from: Abbvie, Pfizer, Novartis, BMS, Nordic, Sanofi, Consultant for: Abbvie, Pfizer, Novartis, BMS, Nordic, Sanofi, Sandoz, Lilly, Paid instructor for: Pfizer, Speakers bureau: Pfizer, Novartis, UCB, Nordic, Sanofi, Sandoz, Lilly, Novartis, Pfizer, UCB, Astra Zeneca, Medçi.

Disclosure of Interests: Shareholder of: Novartis, BMS, Employee of: Novartis, Luminita Prpic Shareholder of: Novartis, Employee of: Novartis, Corinne Galliez Shareholder of: Novartis, BMS, Employee of: Novartis


FRI0459

OBJECTIVE MEASURES OF PSORIASIS SEVERITY AND THE RISK FOR PSA: RESULTS FROM THE INCIDENT HEALTH OUTCOMES AND PSORIASIS EVENTS PROSPECTIVE COHORT STUDY

Alexis Ogdie1, Daniel Shin2, Hyon Choe3, Christopher T. Ritchlin3, Joseph F. Merola4, Jose Scher5, Thorvardur Jon Love6, Joel Gelfand7, 1University of Pennsylvania, Philadelphia, PA, United States of America; 2Massachusetts General Hospital; Harvard Medical School, Boston, MA, United States of America; 3University of Rochester, Rochester, NY, United States of America; 4Bingham and Women’s Hospital; Harvard Medical School, Boston, MA, United States of America; 5New York University, New York, NY, United States of America; 6University of Iceland, Reykjavik, Iceland

Background: Psoriasis severity is a presumed risk factor for development of psoriatic arthritis (PsA) but most studies have examined this question retrospectively. Additionally, it remains unclear whether obesity and body surface area of psoriasis (BSA) are independent risk factors for PsA.

Objectives: We examined the association of psoriasis severity, obesity and other potential risk factors for the development of PsA in patients with psoriasis.

Methods: Between 2008-2011, patients with at least one code for psoriasis aged 25-60 years in The Health Improvement Network were randomly selected and questionnaires were sent to their general practitioners (GPs). GPs were asked to confirm the diagnosis of psoriasis and provide the patient’s approximate BSA that the patient typically demonstrates based on categories commonly used for epidemiological studies. Data through 2015 were used in the current analysis. After excluding patients with PsA at baseline, the incidence of PsA among patients with psoriasis was calculated. Cox proportional hazard ratios were used to examine the risk of developing PsA among patients with mild (<3%), moderate (3-10%), severe (>10%) psoriasis. We also examined other covariates including obesity, depression, recent infections, smoking, and comorbidities in univariable models. Factors significant at the univariable level were included in multivariable models. We additionally tested an interaction between BSA and obesity.

Results: Among 10,474 questionnaires sent, 9,987 (95%) were returned and, of those, 9,069 (91%) had confirmed psoriasis. The mean age was 46 and 53% were female. BSA was provided for 8,881 patients of which 52% had mild psoriasis, 36% moderate psoriasis, and 12% severe psoriasis. Mean follow up time was 4.2 years (SD 2.1); the incidence of PsA was 5.4 cases per 1,000 person years. In univariable models, age and sex were not associated with PsA but obesity, BMI (continuous), and depression were significantly associated with development of PsA. The final multivariable model included BSA category (ref mild, moderate: HR 1.44, 95%CI: 1.02-2.03; severe HR 1.99, 1.28-3.11), history of depression (1.69, 1.22-2.34), obesity (1.64, 1.19-2.25), age (HR 0.99, 0.98-1.00) and female sex (HR 0.72, 0.52-0.99). There was not a statistically significant interaction between BSA and obesity although patients that were obese and had >10% BSA had the highest risk (HR 3.90, 2.22-6.85).

Conclusion: In this large prospective cohort study, we found that body surface area is a strong predictor of developing psoriasis over the next 4-7 years and obesity is an additive risk factor.

REFERENCES:


Acknowledgement: Funded by NIH/NIAMS K23 AR063764

Disclosure of Interests: Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Pfizer, Grant/research support from: Novartis, Pfizer, Pfizer, Grant/research support from: Novartis, Pfizer, Pfizer, Consultant for: Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Daniel Shin: None declared, Hyon Choi: None declared, Christopher T. Ritchlin Grant/research support from: Abbvie, Amgen, UCB Pharma, Consultant for: Abbvie, Amgen, Pfizer, Novartis, Pfizer, UCB, speakers bureau: Abbvie, Amgen, BMS, Sandoz, Lilly, Novartis, Pfizer, UCB, Astra Zeneca, Medci.

Disclosure of Interests: Shareholder of: Novartis, BMS, Employee of: Novartis, Luminita Prpic Shareholder of: Novartis, Employee of: Novartis, Corinne Galliez Shareholder of: Novartis, BMS, Employee of: Novartis


FRI0459

PREVALENCE OF DISEASE DOMAIN PRESENTATIONS AMONG PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE CORRONA PSORIATIC ARTHRITIS/SPODYLARTHRITIS (PSA/SPA) REGISTRY

Alexis Ogdie1, Peter Hur2, Mei Li2, Sabrina Rebelito3, Robert Mclean4, Blessing Dube5, Meghan Glynn5, Philip J. Mease6, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, United States of America; 2Novartis Pharmaceuticals Corporation, East Hanover, United States of America; 3Corrona, LLC, Waltham, United States of America; 4Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, United States of America

Background: Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease of the skin and musculoskeletal system. Six key domains of PsA have been identified to help guide treatment: peripheral arthritis, axial disease, enthesitis, dactylitis, and psoriatic skin and nail disease.

Understanding the epidemiology of these different disease presentations is important for the management and treatment of PsA, yet there is limited evidence available.

Objectives: To describe the prevalence of disease domain presentations among patients with PsA at enrollment in the Corrona PsA/SpA Registry.

Methods: This study included adult patients with PsA enrolled in the Corrona PsA/SpA Registry between March 2013 and August 2018. Patients were evaluated for the presence of 6 disease domain presentations: enthesitis (Spondylarthritides Research Consortium of Canada enthesitis count > 0), dactylitis (dactylitis count > 0), peripheral arthritis (PA: tender and/or swollen joint count > 0), nail psoriasis (global nail psoriasis visual analog scale > 0), axial disease (physician-reported presence of spinal involvement, based on clinical judgment/or radiographs or MRI showing sacroiliitis), and skin disease (BSA > 0%). The most common mutually exclusive disease presentations were summarized among all patients

Disclosure of Interests: Alexis Ogdie Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Pfizer, Grant/research support from: Novartis, Pfizer, Pfizer, Consultant for: Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Daniel Shin: None declared, Hyon Choi: None declared, Christopher T. Ritchlin Grant/research support from: Abbvie, Amgen, UCB Pharma, Consultant for: Abbvie, Amgen, Pfizer, Novartis, Pfizer, UCB, speakers bureau: Abbvie, Amgen, BMS, Sandoz, Lilly, Novartis, Pfizer, UCB, Astra Zeneca, Medci.

Disclosure of Interests: Shareholder of: Novartis, BMS, Employee of: Novartis, Luminita Prpic Shareholder of: Novartis, Employee of: Novartis, Corinne Galliez Shareholder of: Novartis, BMS, Employee of: Novartis
